The Emergence of Psilocybin in Psychiatry and Neuroscience.
Study Goal
The researchers aimed to systematically review the latest research on psilocybin's pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile for treating psychiatric and neurological disorders.
Results Summary
Emerging evidence supports psilocybin's efficacy in treating major depressive disorder, treatment-resistant depression, anxiety, alcohol use disorders, and cancer-related distress, though methodological and regulatory barriers remain. Advances in biosynthetic production and psychotherapeutic integration are needed for scalability and accessibility.
Population
Patients with psychiatric and neurological disorders (e.g., MDD, TRD, anxiety, AUD, cancer-related distress).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
psilocybin | decrease | major depressive disorder (MDD) | - | - | supports its efficacy | #1 |
psilocybin | decrease | treatment-resistant depression (TRD) | - | - | supports its efficacy | #2 |
psilocybin | decrease | anxiety | - | - | supports its efficacy | #3 |
psilocybin | decrease | alcohol use disorders (AUD) | - | - | supports its efficacy | #4 |
psilocybin | decrease | cancer-related distress | - | - | supports its efficacy | #5 |
Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin's pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.